Periorbital myxedema treated with intralesional hyaluronidase

PURPOSE: Periorbital myxedema is one the most challenging symptoms for patients with Graves' eye disease (GED). The treatment of this condition is complex and often unsatisfactory. This case demonstrates the use of intralesional hyaluronidase to treat cosmetically concerning periorbital myxedem...

Descripción completa

Detalles Bibliográficos
Autores principales: Lindgren, Aleksandra L., Sidhu, Sharleen, Welsh, Kathleen M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7262547/
https://www.ncbi.nlm.nih.gov/pubmed/32490285
http://dx.doi.org/10.1016/j.ajoc.2020.100751
_version_ 1783540648303919104
author Lindgren, Aleksandra L.
Sidhu, Sharleen
Welsh, Kathleen M.
author_facet Lindgren, Aleksandra L.
Sidhu, Sharleen
Welsh, Kathleen M.
author_sort Lindgren, Aleksandra L.
collection PubMed
description PURPOSE: Periorbital myxedema is one the most challenging symptoms for patients with Graves' eye disease (GED). The treatment of this condition is complex and often unsatisfactory. This case demonstrates the use of intralesional hyaluronidase to treat cosmetically concerning periorbital myxedema. OBSERVATIONS: Follow up showed no clinically significant recurrence of myxedema over one year. CONCLUSION: Intralesional hyaluronidase represented an effective and safe treatment of periorbital myxedema in a patient with Graves' eye disease.
format Online
Article
Text
id pubmed-7262547
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-72625472020-06-01 Periorbital myxedema treated with intralesional hyaluronidase Lindgren, Aleksandra L. Sidhu, Sharleen Welsh, Kathleen M. Am J Ophthalmol Case Rep Case Report PURPOSE: Periorbital myxedema is one the most challenging symptoms for patients with Graves' eye disease (GED). The treatment of this condition is complex and often unsatisfactory. This case demonstrates the use of intralesional hyaluronidase to treat cosmetically concerning periorbital myxedema. OBSERVATIONS: Follow up showed no clinically significant recurrence of myxedema over one year. CONCLUSION: Intralesional hyaluronidase represented an effective and safe treatment of periorbital myxedema in a patient with Graves' eye disease. Elsevier 2020-05-25 /pmc/articles/PMC7262547/ /pubmed/32490285 http://dx.doi.org/10.1016/j.ajoc.2020.100751 Text en © 2020 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Lindgren, Aleksandra L.
Sidhu, Sharleen
Welsh, Kathleen M.
Periorbital myxedema treated with intralesional hyaluronidase
title Periorbital myxedema treated with intralesional hyaluronidase
title_full Periorbital myxedema treated with intralesional hyaluronidase
title_fullStr Periorbital myxedema treated with intralesional hyaluronidase
title_full_unstemmed Periorbital myxedema treated with intralesional hyaluronidase
title_short Periorbital myxedema treated with intralesional hyaluronidase
title_sort periorbital myxedema treated with intralesional hyaluronidase
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7262547/
https://www.ncbi.nlm.nih.gov/pubmed/32490285
http://dx.doi.org/10.1016/j.ajoc.2020.100751
work_keys_str_mv AT lindgrenaleksandral periorbitalmyxedematreatedwithintralesionalhyaluronidase
AT sidhusharleen periorbitalmyxedematreatedwithintralesionalhyaluronidase
AT welshkathleenm periorbitalmyxedematreatedwithintralesionalhyaluronidase

Ejemplares similares